Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

129.44 +3.85 (+3.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
From Robbins Geller Rudman
Via Business Wire
The 3 Best Healthcare Stocks to Buy in June 2024
Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on. 
Via InvestorPlace
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga
Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm
From Kirby McInerney LLP
Via GlobeNewswire
4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024
Consider making moves in these securities, each of which has news that is impacting their share price either positively or negatively. 
Via InvestorPlace
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi. 
Via Benzinga
Exposures Product Safety
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. 
Via Investor's Business Daily
Exposures Product Safety
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting... 
Via Benzinga
Exposures Product Safety
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
The FDA isn't bound by the committee's recommendation, but often follows it. 
Via Investor's Business Daily
Exposures Product Safety
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
BIIB Class Action Reminder: Contact Robbins LLP for Information About Your Rights Against Biogen Inc.
From Robbins LLP
Via GlobeNewswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biogen Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines. 
Via InvestorPlace
Topics Economy
Exposures Economy
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
From Glancy Prongay & Murray LLP
Via Business Wire
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
Robbins LLP Urges BIIB Investors With Large Losses to Contact the Firm for Information About the Biogen Inc. Class Action
From Robbins LLP
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)
From Law Offices of Howard G. Smith
Via Business Wire
Biogen Shares Surge Following Collaboration With Delta Flight Products: What You Need To Know
Biogen Inc. (NASDAQ: BIIB) shares saw a notable uptick Monday afternoon, trading higher after the company revealed a new partnership with Delta Flight Products (DFP) to enhance air travel accessibility... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel
From Biogen Inc.
Via GlobeNewswire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.